<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>OmniSeq Page 6</title>
    <link href="https://fonts.googleapis.com/css?family=Lato&display=swap" rel="stylesheet">

     <link rel="stylesheet" type="text/css" href="{{ STATIC_PREFIX }}css/main.css">
</head>
<body>
<!--
About OmniSeq CDx
-->
<img src="{{ STATIC_PREFIX }}IntegratedOncology.jpg" width="150" />

<img class="Omniseq_logo" src="{{ STATIC_PREFIX }}omniseqCdx_logo.png" />

<div class="Vertical_Spacer_10"></div>

<div class="About_Wrapper">
    <div>About <br/>OmniSeq <br/>CDx</div>
    <div>OmniSeq CDx is a next generation sequencing based in vitro diagnostic device for the detection of single nucleotide variants (SNVs), small and large insertions and deletions (indels), copy number variants (CNVs), rearrangements (fusions), as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA and RNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue samples.  OmniSeq CDx is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies with approved companion diagnostic indications in accordance with FDA approved therapeutic product labeling.  Additionally, OmniSeq CDx is intended to provide comprehensive genomic and immune profiling for qualified healthcare professionals in accordance with professional guidelines and standard oncology care for patients with solid tumor malignant neoplasms. OmniSeq CDx is a single site assay performed at OmniSeq, Inc., Buffalo, NY.</div>

</div>

<div class="Section_Header">COMPANION DIAGNOSTIC INDICATIONS</div>
<div class="CDX_Indications_Header_Wrapper">
    <div>Indication</div>
    <div>Biomarker</div>
    <div>Therapy</div>
</div>


<div class="CDX_Indications_Wrapper">
    <div class="CDX_Indication">
        <div class="CDX_Indication_Text">Non-small cell lung cancer (NSCLC)</div>
    </div>
    <div class="Nested_CDX_Indications_Wrapper">
            <div>EGFR exon 19 deletions EGFR exon 21 L858R alterations</div>
            <div>Iressa® (gefitinib<br/>
                    Tarceva® (erlotinib)<br/>
                    Tagrisso (osimertinib)<br/>
                    Vizimpro (dacomitinib)
            </div>

            <div>EGFR exon 20 T790M alterations</div>
            <div>Tagrisso® (osimertinib)</div>

            <div>EGFR exon 19 deletions, EGFR L858R, EGFR L861Q, EGFR G719X, EGFR G719S, EGFR G719A, EGFR, G719C, EGFR S768I, EGFR exon 20 insertions</div>
            <div>Gilotrif® (afatinib)</div>

            <div>ALK rearrangements</div>
            <div>Alecensa® (alectinib)<br/>
                    XALKori® (crizotinib)<br/>
                    Zykadia® (ceritinib)
            </div>

            <div>BRAF V600E</div>
            <div>Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib)</div>

            <div>ROS1 rearrangements</div>
            <div>XALKori® (crizotinib)</div>
    </div>
    <div class="CDX_Indication">
        <div class="CDX_Indication_Text">Melanoma</div>
    </div>
    <div class="Nested_CDX_Indications_Wrapper">
            <div>BRAF V600E and V600K</div>
            <div>Tafinlar® (dabrafenib) or<br/>
                    Zelboraf® (vemurafenib)
            </div>

            <div>BRAF V600E and V600K</div>
            <div>Mekinist® (trametinib)<br/>
                    Cotellic® (cobimetinib) in combination with Zelboraf® (vemurafenib)<br/>
                    Mektovi® (binimetinib) in combination with Braftovi™ (encorafenib)<br/>
            </div>

    </div>

    <div class="CDX_Indication">
        <div class="CDX_Indication_Text">Breast cancer</div>
    </div>
    <div class="Nested_CDX_Indications_Wrapper">
            <div>PIK3CA C420R, PIK3CA E542K, PIK3CA E545A, PIK3CA E545D, PIK3CA E545G, PIK3CA E545K, PIK3CA Q546E, PIK3CA Q546R, PIK3CA H1047L, PIK3CA H1047R, PIK3CA H1047Y</div>
            <div>PIQRAY (alpelisib)
            </div>

            <div>PD-L1 IHC 22C3 </div>
            <div>Keytruda® (pembrolizumab)
            </div>

            <div>ERBB2 (HER2) amplification</div>
            <div>Herceptin (trastuzumab)<br/>
                Perjeta (pertuzumab)<br/>
                Kadcyla (ado-trastuzumab emtansine)
            </div>
            <div>
                    BRCA1 deleterious mutation<br/>
                    BRCA 2 deleterious mutation
            </div>
            <div>Rubraca® (rucaparib)
            </div>
    </div>
    <div class="CDX_Indication">
        <div class="CDX_Indication_Text">Colorectal cancer</div>
    </div>
    <div class="Nested_CDX_Indications_Wrapper">
            <div>KRAS wild-type (absence of mutations in codons 12 and 13)</div>
            <div>Erbitux® (cetuximab)
            </div>

            <div>KRAS wild-type (absence of mutations in exons 2, 3, and 4) and NRAS wild type (absence of mutations in exons 2, 3, and 4)</div>
            <div>Vectibix® (panitumumab)
            </div>

    </div>

    <div class="CDX_Indication">
        <div class="CDX_Indication_Text">Ovarian cancer</div>
    </div>
    <div class="Nested_CDX_Indications_Wrapper">
            <div>BRCA1/2 alterations<br/>
                    BRCA1 deleterious mutation<br/>
                    BRCA 2 deleterious mutation
            </div>
            <div>Rubraca® (rucaparib)<br/>
                    Lynparza® (olaparib)<br/>
                    Talzenna® (talazoparib)

            </div>
    </div>

    <div class="CDX_Indication">
        <div class="CDX_Indication_Text">Gastric/gastroesophaeal junction cancer</div>
    </div>
    <div class="Nested_CDX_Indications_Wrapper">
            <div>ERBB2 (HER2) amplification</div>
            <div>Herceptin (trastuzumab)
            </div>

    </div>
    <div class="CDX_Indication">
        <div class="CDX_Indication_Text">Urothelial carcinoma</div>
    </div>
    <div class="Nested_CDX_Indications_Wrapper">
            <div>FGFR2-BICC1 fusion, FGFR2-CASP7 fusion, FGFR3 R248C, FGFR3 S249C, FGFR3 G370C, FGFR3 Y373C, FGFR3-BAIAP2L1 fusion, FGFR3-TACC3 fusion</div>
            <div>Balversa (erdafitinib)
            </div>


    </div>

</div>

<div class="Vertical_Spacer_50"></div>
<div class="Vertical_Spacer_50"></div>
<div class="Footer">
     {{patient['test_id']}}&nbsp;P-20-00000-000 VERSION 1 | Report electronically signed by George Who, MD
    |{{patient['sign_out_date']}} <br>
    CLIA ID: 33D2098748 | CAP # 9405346 | OmniSeq Inc., 700 Ellicott Street, Buffalo NY 14203 | 1 (800) 781-1259
<img class="Cap_logo" src="{{ STATIC_PREFIX }}cap_logo.png" width="75" />
</div>
</body>
</html>